Yazar "Yilmaz, Vural Taner" seçeneğine göre listele
Listeleniyor 1 - 8 / 8
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe THE ASSESMENT OF LONG TERM OUTCOMES IN HBSAG NEGATIVE RENAL TRANSPLANT RECIPIENTS WHO WERE TRANSPLANTED FROM HBSAG POSITIVE DONORS(Wiley-Blackwell, 2015) Yilmaz, Vural Taner; Ulger, Burak Veli; Aliosmanoglu, Ibrahim; Erbis, Halil; Tuna, Yasar; Akbas, Halide; Ozdem, Sebahat[Abstract Not Available]Öğe Assessment of Long-Term Outcomes in Hbs Ag-Negative Renal Transplant Recipients Transplanted from Hbs Ag-Positive Donors(Int Scientific Information, Inc, 2015) Yilmaz, Vural Taner; Ulger, Burak Veli; Aliosmanoglu, Ibrahim; Erbis, Halil; Tuna, Yasar; Akbas, Halide; Ozdem, SebahatBackground: The aim of this study was to evaluate the long-term outcomes of renal transplantation from Hbs Ag-positive donors to Hbs Ag-negative recipients. Material/Methods: A total of 78 patients who underwent renal transplantation in our clinic between January 2006 and May 2014 were included in the study. Patients were divided into 2 groups: Group 1: Donor Hbs Ag (+) (n=26, Hbs Ab (-), Hbe Ag (-), Hbe Ab (+), Hbc Ig total (+) and HBV DNA (+), male/female (M/F): 16 (61.5%)/10 (38.5%), and Group 2: Donor Hbs Ag (-) (n=52, M/F: 41 (78.8%)/11 (21.2%). Hbs Ab levels were similar in recipients in both groups. Data were collected retrospectively. Analyses were performed by using SPSS 20.0 software, and patient and graft survival were measured by using Kaplan-Meier survival curve and compared by using the log-rank test. Results: Demographic data were similar in the 2 groups. The rate of acute Hepatitis B infection was significantly higher in Group 1 than in Group 2 [n=3 (11.5%) vs. n=0 (0%), respectively, p=0.012]. Acute hepatitis B attacks were detected in vaccinated patients. Graft survival rates (groups 1 and 2, respectively; at 1st, 3rd, 5th and 8th years: 95% vs. 96%, 95% vs. 94%, 85% vs. 88%, 85% vs. 82%, p=0.970) and patient survival rates (p=0.098), acute rejection rates (p=0.725), delayed graft function, chronic allograft dysfunction, new-onset diabetes after transplantation (NODAT), cytomegalovirus infection, and the need for postoperative dialysis and plasmapheresis were similar between groups. Conclusions: Our study revealed that the risk of developing acute hepatitis B was higher in patients renally transplanted from Hbs Ag (+) donors, but the other clinical outcomes were similar between groups.Öğe HEPATOPULMONARY SYNDROME RELATED PORTAL HYPERTENSION(Wiley-Blackwell, 2015) Erbis, Halil; Calli, Iskan; Mutlu, Fatih; Ulger, Burak Veli; Tuna, Yasar; Ozturk, Bunyamin; Yilmaz, Vural Taner[Abstract Not Available]Öğe Nebivolol Ameliorates Hepatic Ischemia/Reperfusion Injury on Liver But Not on Distant Organs(Taylor & Francis Inc, 2015) Ulger, Burak Veli; Erbis, Halil; Turkcu, Gul; Ekinci, Aysun; Turkoglu, Mehmet Akif; Ekinci, Cenap; Yilmaz, Vural TanerIntroduction: Hepatic ischemia/reperfusion injury may occur after large tumor resection and liver transplantation procedures. Nitric oxide was shown to have protective effects on ischemia/reperfusion injury. Nebivolol is a compound that has been reported to improve nitric oxide release. We evaluated the effects of nebivolol in a rat liver ischemia/reperfusion model. Methods: A total of 40 rats were randomly divided into four groups (n = 10 each). Group I underwent only laparotomy, Group II was administered nebivolol and then underwent laparotomy, Group III underwent laparotomy and hepatic ischemia/reperfusion, and Group IV was administered nebivolol and then underwent laparotomy and hepatic ischemia/reperfusion. Serum AST, ALT, urea, and creatinine levels, and TAS and TOS levels of liver, lung, and kidney tissues were determined. Histopathological determination was also performed. Results: Nebivolol significantly reduced liver function tests in group IV, but it did not improve renal functions. Oxidative stress and abnormal histopathological findings were found to be reduced in liver tissue in group IV. Although the oxidative stress was increased after hepatic ischemia/reperfusion, nebivolol could not reduce the oxidative stress in kidney tissue. There were no significant differences between group III and group IV in terms of the histopathological changes in kidney tissue. There were no significant differences in lung tissue between the groups. Conclusions: The results of this study suggest that nebivolol has protective effects on liver but not on distant organs in a hepatic ischemia/reperfusion injury model. These experimental findings indicate that nebivolol may be useful in the treatment of hepatic ischemia/reperfusion injury.Öğe RECONSTRUCTION OF SEGMENT 5 AND 8 VEINS IN RIGHT LOBE LIVING DONOR LIVER TRANSPLANTATION: AKDENIZ UNIVERSITY EXPERIENCE(Wiley-Blackwell, 2015) Aliosmanoglu, Ibrahim; Ulger, Burak Veli; Erbis, Halil; Tuna, Yasar; Ozturk, Bunyamin; Yilmaz, Vural Taner; Dinckan, Ayhan[Abstract Not Available]Öğe RETRO-URETERAL INTERNAL HERNIA AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION: A VERY RARE CASE(Wiley-Blackwell, 2015) Ulger, Burak Veli; Aliosmanoglu, Ibrahim; Erbis, Halil; Yilmaz, Vural Taner; Ozturk, Bunyamin; Calli, Iskan; Mutlu, Fatih[Abstract Not Available]Öğe Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients(Taylor & Francis Inc, 2016) Yilmaz, Vural Taner; Suleymanlar, Gultekin; Koksoy, Sadi; Ulger, Burak Veli; Ozdem, Sebahat; Akbas, Halide; Akkaya, BaharIntroduction: The aim of our study was to determine the effectiveness of immunoglobulin, rituximab and plasmapheresis in renal transplant patients with antibody mediated rejection (AMR). Patients and Methods: Fourteen renal transplant patients with AMR were included in this study. The mean age of the patients was 33.9 +/- 10.3years and 10 (71.4%) of them were male. Lymphocyte cross match was negative for all patients and 10 (71.4%) of them were living donor transplants. Six patients were administered tacrolimus, three patients cyclosporine, two patients everolimus, and three patients sirolimus for immunosuppression. The patients with AMR were administered IVIG, rituximab and plasmapheresis. Results: Patient survival rate was 100%, graft survival rate after AMR was 50% in the first year and 33% in the 2nd and third years. AMR developed 31.9 +/- 25.9 months after transplantation. Seven (50%) patients lost their grafts. Delayed graft function was observed in 28.6%, chronic allograft dysfunction in 78.5%, diabetes after transplantation in 14.3%, and cytomegalovirus infection in 7.1% of the patients. At the last follow-up, the mean blood creatinine was 3.1 +/- 1.4, the mean proteinuria was 2300 (1300-3300) mg/day and the mean GFR was 34.5 +/- 17.6ml/min. C4d was positive in peritubullar capillaries in all patients, while neutrophil accumulation in peritubular and glomerular capillaries was observed in 8 patients. Chronic allograft vasculopathy was observed in 12 patients. Conclusion: AMR leads to progressive loss of renal function and has low graft survival. More effective treatment alternatives are needed for this clinical issue.Öğe AN UNUSUAL CAUSE OF BILIARY OBSTRUCTION AFTER LIVER TRANSPLANTATION: FASCIOLA HEPATICA(Wiley-Blackwell, 2015) Erbis, Halil; Ulger, Burak Veli; Aliosmanoglu, Ibrahim; Ozturk, Bunyamin; Yilmaz, Vural Taner; Dinckan, Ayhan[Abstract Not Available]
